PRTN3 and rheumatoid arthritis: Elevated in 60–75% of RA patients with a specificity of 78–93%, this marker demonstrates particularly strong additive value; combined RF, ACPA, and 14-3-3η testing achieves sensitivity exceeding 80% for early RA [23,25].